A room full of oncologists does not cry. They did in Chicago.

The moment that stopped a room of cancer doctors cold

At the 2026 ASCO Annual Meeting in Chicago, Dr. Brian Wolpin of Dana-Farber Cancer Institute showed a single slide. The audience erupted for 42 seconds straight: cheering, whistling, yelling. The slide showed that a drug called daraxonrasib had cut the risk of death by 60% in patients with metastatic pancreatic cancer compared to standard chemotherapy.

I have followed cancer research for years and I cannot remember a moment like this. Pancreatic cancer has a 5-year survival rate of roughly 3% once it spreads. For four decades, researchers called the KRAS gene driving most of these tumors "undruggable." That word is now retired.

“The RAS revolution is here, and this study is proof of principle that targeting KRAS in pancreatic cancer is feasible and effective.”

— Dr. Rachna Shroff, University of Arizona Cancer Center, ASCO Expert

The phase 3 RASolute 302 trial enrolled 500 patients. Median overall survival was 13.2 months on daraxonrasib versus 6.7 months on chemotherapy. That gap is not a rounding error. It is nearly double the time alive, with fewer serious side effects. The results were published simultaneously in the New England Journal of Medicine on the same day they were presented.

Why this pill is different from everything that came before

Daraxonrasib is not chemotherapy. It is an oral, once-daily pill that works as a molecular glue — it locks onto the active, switched-on form of RAS proteins and blocks them from firing the signals that tell cancer cells to grow. Roughly 90% of pancreatic cancer patients carry a mutation in the KRAS gene. This drug targets that mutation directly, across multiple mutation types, not just one narrow variant.

The safety profile is also genuinely good news. Grade 3 or higher adverse events hit 43.6% of daraxonrasib patients versus 57.5% on chemotherapy. Treatment discontinuation due to side effects was 1.2% on the drug versus 11.2% on chemo. Patients on daraxonrasib also reported better quality of life and delayed time to pain deterioration.

This is genuinely smart science. Revolution Medicines built this drug on structural chemistry insights that only became possible in the last decade. The FDA already granted daraxonrasib Breakthrough Therapy designation, and the company has submitted data for formal approval.

Now for the part that should make you furious

Here is the bitter irony sitting right next to this triumph. The National Cancer Institute is spending 80% less than its typical pace on new grants so far in 2026. By late March, the NCI had earmarked only $72 million for new competitive research grants, compared to nearly $250 million it would normally commit by that point in the year.

The Trump administration's proposed FY2026 budget cuts the National Cancer Institute by 37.2%, from roughly $7.2 billion down to $4.53 billion. The NIH overall faces a nearly 40% reduction. Congress pushed back and rejected the steepest cuts, but the damage to grant pipelines, lab hiring, and early-career researchers is already real.

This is unserious governance. You cannot celebrate a cancer breakthrough with one hand while defunding the basic research ecosystem that produces the next one with the other.

“For the past 50 years, every significant medical breakthrough, especially in the treatment of cancer, has been linked to sustained federal investment in research at NIH and NCI.”

— American Cancer Society Cancer Action Network

The counterargument, and why it does not hold

Some will say daraxonrasib was funded by Revolution Medicines, a private company, so the government cuts do not matter here. That argument is lazy. The foundational science that identified the KRAS binding pocket, that mapped RAS protein structure, that trained the researchers who designed this trial — that came from decades of publicly funded basic research.

Private capital does not fund curiosity-driven science. It funds the last mile. When you cut the first 90 miles, you eventually run out of last miles to fund.

When was the last time you heard a politician explain that connection clearly? I do not buy the idea that the public does not care. Pancreatic cancer kills roughly 50,000 Americans every year. Every family has someone. The politics of cutting cancer research funding should be radioactive. Instead it is treated as a line-item negotiation.

What happens next, and what we owe the people waiting

The FDA review of daraxonrasib is underway. On May 1, 2026, the FDA granted Revolution Medicines permission to begin an expanded access program so that patients with previously treated metastatic pancreatic cancer can access the drug before full approval. That is the right call. People with a 3% five-year survival rate cannot wait for bureaucratic timelines.

A follow-on trial, RASolute 303, is already testing daraxonrasib as a first-line treatment for metastatic pancreatic cancer. If those results hold, we are looking at a genuine paradigm shift. The question is whether the research infrastructure will survive long enough to deliver the next generation of drugs that build on this one.

Science delivered something extraordinary this month. Politics is now the variable that determines whether it was a turning point or a one-off. Tell me that is acceptable.